Literature DB >> 848665

Distribution of 5-fluorouracil to body tissues compared after intraluminal, intravenous, and intramural administration in gastrointestinal cancer.

H S Shukla, L E Hughes, P W Davis, R H Whitehead, K G Leach.   

Abstract

The distribution of 5-fluorouracil (5-FU) to various potential metastatic sites has been investigated in stomach and colorectal cancer patients, using intraluminal, intravenous, and intramural routes of administration at the time of surgery. The best overall concentrations of 5-FU in systemic blood, portal blood, liver, draining lymph nodes, tumor, and locally in the bowel wall was obtained after intramural injection. The intraluminal route of administration resulted in poor overall distribution of 5-FU. Intravenous administration tended to give levels between those obtained from intramural and intraluminal routes. There was no complication of 5-FU therapy. On the basis of this study we conclude that the intramural route is the most satisfactory for adjuvant administration of 5-FU with surgery. This might be expected to give better results than those obtained in clinical studies using intraluminal and intravenous routes. A controlled trial of 5-FU using the intramural route is indicated in gastric and colorectal cancer to demonstrate whether or not clinical benefit can be obtained.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 848665     DOI: 10.1016/0002-9610(77)90543-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Suppository delivery of 5-fluorouracil in rectal cancer.

Authors:  S Galandiuk; W Wrightson; L Marr; S Myers; R V LaRocca
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

2.  Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).

Authors:  Rong-Xin Zhang; Jun-Zhong Lin; Jian Lei; Gong Chen; Li-Ren Li; Zhen-Hai Lu; Pei-Rong Ding; Jiong-Qiang Huang; Ling-Heng Kong; Fu-Long Wang; Cong Li; Wu Jiang; Chuan-Feng Ke; Wen-Hao Zhou; Wen-Hua Fan; Qing Liu; De-Sen Wan; Xiao-Jun Wu; Zhi-Zhong Pan
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

3.  Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer.

Authors:  B Nishioka; S Watanabe; Y Fijita; O Kojima; K Morisawa; E Yamane; M Umehara; S Majima
Journal:  Jpn J Surg       Date:  1980-06

4.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.